卵巢上皮癌患者血浆中循环游离 DNA 和 p53 抗体。

Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers.

机构信息

Department of Obstetrics, Gynecology and Obstetrics/Gynecological Care, Medical University of Bialystok.

出版信息

Ann Oncol. 2011 May;22(5):1133-1140. doi: 10.1093/annonc/mdq584. Epub 2010 Nov 23.

DOI:10.1093/annonc/mdq584

PMID:21098618

Abstract

BACKGROUND

This study was conducted in order to evaluate the significance of circulating free DNA (CFDNA), blood plasma p53 antibodies (p53-Ab) and mutations of KRAS gene in the prognosis of ovarian epithelial cancers.

PATIENTS AND METHODS

A total of 126 patients were included in this study. KRAS mutations and CFDNA were detected by means of the PCR-restriction fragment length polymorphism (PCR-RFLP) and enriched by the PCR-RFLP method. Enzyme-linked immunosorbent assay was used to analyze plasma p53-Ab.

RESULTS

KRAS mutations were detected in 27 (21.4%) of examined tumors. The frequency of KRAS mutations was especially high in mucinous cancers (P < 0.001). CFDNA and p53-Ab were frequently detected in patients with serous cancers in high grade (P < 0.001). The overall survival rate was significantly lower for patients with serous tumors and CFDNA and p53-Ab-positive than negative tumors (P = 0.022 and P < 0.001, respectively). In mucinous ovarian cancer, a worse overall survival was correlated with the KRAS mutations (P = 0.03).

CONCLUSIONS

The results of the present study suggested that a presence of KRAS mutations in mucinous ovarian cancer and CFDNA and p53-Ab in serous tumors was correlated with the highest risk of cancer progression.

摘要

背景

本研究旨在评估循环游离 DNA（cfDNA）、血浆 p53 抗体（p53-Ab）和 KRAS 基因突变在卵巢上皮性癌预后中的意义。

患者和方法

本研究共纳入 126 例患者。采用 PCR-限制性片段长度多态性（PCR-RFLP）检测 KRAS 基因突变，并用 PCR-RFLP 法富集。采用酶联免疫吸附试验分析血浆 p53-Ab。

结果

在检测的肿瘤中，27 例（21.4%）检测到 KRAS 基因突变。黏液性癌中 KRAS 基因突变的频率特别高（P<0.001）。高级别浆液性癌患者中 cfDNA 和 p53-Ab 频繁检测到（P<0.001）。cfDNA 和 p53-Ab 阳性肿瘤患者的总生存率明显低于阴性肿瘤患者（P=0.022 和 P<0.001）。在黏液性卵巢癌中，KRAS 基因突变与较差的总生存率相关（P=0.03）。